ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
93,123.23
-4.45%
S&P 500
5,867.08
-0.09%
Dow Jones
42,342.24
0.04%
US Dollar vs Yen
156.7005
-0.61%
Brent Oil
71.755
-0.87%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. カナダ
  5. TSXV

  6. Arch Biopartners Inc (ARCH) 銘柄情報

Arch Biopartners Inc

Arch Biopartners Inc (ARCH)

Arch Resources Inc
1.72
0.00
(0.00%)
終了 12月20日 6:00AM
15分遅延

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

主要統計と詳細

通貨
1.72
買値
1.72
売値
1.73
出来高
-
0.00 日の範囲 0.00
1.31 52 週間の範囲 2.56
時価総額
107.669M
前日終値
1.72
始値
-
時刻
最終取引時間
財務取引量
-
VWAP
-
平均取引量 (3 か月)
16,155
発行済株式数
62,598,000
配当利回り
-
PER
-32.02
1 株当たり利益 (EPS)
-0.05
歳入
1.98M
純利益
-3.33M

Arch Biopartners Inc について

セクター
Coml Physical, Biologcl Resh
業界
Advertising Agencies
ウェブサイト
archbiopartners.com
本社
Toronto, Ontario, Can
設立
2010
Arch Biopartners Inc is listed in the Coml Physical, Biologcl Resh sector of the トロントベンチャー取引所 with ticker ARCH. The last closing price for Arch Biopartners was $1.72. Over the last year, Arch Biopartners shares have traded in a share price range of $ 1.31 to $ 2.56.

Arch Biopartners currently has 62,598,000 shares in issue. The market capitalisation of Arch Biopartners is $107.67 million. Arch Biopartners has a price to earnings ratio (PE ratio) of -32.02.

ARCH 最新ニュース

その他のニュース

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun...

2024年11月11日
GlobeNewswire Inc.

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

2024年10月16日
GlobeNewswire Inc.

Closes Units for Debt Settlement

TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that...

2024年10月3日
GlobeNewswire Inc.

Units for Debt Settlement

TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to...

2024年9月26日
GlobeNewswire Inc.

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved...

2024年9月11日
GlobeNewswire Inc.

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its...

2024年8月2日
GlobeNewswire Inc.

Arch Biopartners Closes Non-Brokered Private Placement

TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement...

2024年7月31日
GlobeNewswire Inc.

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...

2024年7月30日
GlobeNewswire Inc.

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced that Dalton Pharma Services (Dalton) has completed the...

2024年6月27日
GlobeNewswire Inc.

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary’s Conjoint Health...

2024年6月18日
GlobeNewswire Inc.
期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.15-8.021390374331.871.891.59160961.75246602CS
4-0.24-12.24489795921.9621.59145591.87848488CS
12-0.1-5.494505494511.822.21.59161551.94061513CS
260.010.5847953216371.712.21.36156071.74782381CS
520.2416.21621621621.482.561.31195201.82248399CS
156-2.16-55.67010309283.884.250.97200642.23536188CS
2600.7475.51020408160.985.30.74270431.99153259CS

ARCH - Frequently Asked Questions (FAQ)

What is the current Arch Biopartners share price?
The current share price of Arch Biopartners is $ 1.72
How many Arch Biopartners shares are in issue?
Arch Biopartners has 62,598,000 shares in issue
What is the market cap of Arch Biopartners?
The market capitalisation of Arch Biopartners is CAD 107.67M
What is the 1 year trading range for Arch Biopartners share price?
Arch Biopartners has traded in the range of $ 1.31 to $ 2.56 during the past year
What is the PE ratio of Arch Biopartners?
The price to earnings ratio of Arch Biopartners is -32.02
What is the cash to sales ratio of Arch Biopartners?
The cash to sales ratio of Arch Biopartners is 53.63
What is the reporting currency for Arch Biopartners?
Arch Biopartners reports financial results in CAD
What is the latest annual turnover for Arch Biopartners?
The latest annual turnover of Arch Biopartners is CAD 1.98M
What is the latest annual profit for Arch Biopartners?
The latest annual profit of Arch Biopartners is CAD -3.33M
What is the registered address of Arch Biopartners?
The registered address for Arch Biopartners is 27 ST. CLAIR AVENUE EAST, P.O. BOX 305, TORONTO, ONTARIO, M5V 1M1
What is the Arch Biopartners website address?
The website address for Arch Biopartners is archbiopartners.com
Which industry sector does Arch Biopartners operate in?
Arch Biopartners operates in the ADVERTISING AGENCIES sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0
AAAAAuralite Investments Inc
$ 0.265
(0.00%)
0
AAA.PFirst Tidal Acquisition Corp
$ 0.04
(0.00%)
0
AAAlba Minerals Ltd
$ 0.03
(0.00%)
0
A.HArmor Minerals Inc
$ 0.30
(0.00%)
0
AArmor Minerals Inc
$ 0.45
(0.00%)
0

議論

フィード全体を表示

最近閲覧した銘柄

TSXV
ARCH
Arch Biopartners
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有